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ARTICLE OPEN
Mucosal boosting of H56:CAF01 immunization promotes
lung-localized T cells and an accelerated pulmonary response
to Mycobacterium tuberculosis infection without enhancing
vaccine protection
Joshua S. Woodworth1, Dennis Christensen1, Joseph P. Cassidy2, Else Marie Agger1, Rasmus Mortensen1 and Peter Andersen1,3
T cell-mediated protection against Mycobacterium tuberculosis (Mtb) is dependent upon the ability to localize within the site of
pulmonary infection and directly interact with infected cells. In turn, vaccine strategies to improve rapid T cell targeting of Mtb-
infected cells after pulmonary exposure are being actively pursued. Given parenterally, the subunit vaccine H56:CAF01 elicits
polyfunctional CD4 T cells that localize to the lung parenchyma and confer durable protection. Here, we ﬁnd that airway mucosal
boosting of parenteral H56:CAF01 immunization greatly enhances the population of long-lived lung-resident T cells (Trm) and
increases early vaccine T cell responses to pulmonary Mtb challenge in multiple mouse models. However, mucosal boosting does
not alter the Th1/17 vaccine signature typical of H56:CAF01 and does not further improve durable control of pulmonary infection
following aerosol Mtb-challenge. Additional mucosal boosting with H56:CAF01 further enhances the Trm response without further
improving protection, while blocking the recruitment of non-Trm with FTY720-treatment failed to exposed Trm-mediated
protection in mucosally boosting animals. These results demonstrate the limitations of maximizing lung-localized Trm in vaccine
control of pulmonary Mtb infection, especially within an immunization protocol that is already optimized for the induction of
mucosal-homing Th17 cells.
Mucosal Immunology (2019) 12:816–826; https://doi.org/10.1038/s41385-019-0145-5
INTRODUCTION
One quarter of the world’s population is estimated to be infected
with the bacterium Mycobacterium tuberculosis (Mtb), and tuber-
culosis (TB) disease remains the most common cause of death from
a single infectious agent.1,2 Given this setting, a novel, more
effective anti-TB vaccine strategy is required to achieve the WHO’s
End TB targets of 90% reduction in TB incidence rate by 2035.3
T cell-mediated immunity is critical to control M. tuberculosis
(Mtb) infection and TB disease. However, Mtb actively delays the
adaptive T cell response after initial infection.4 Thus, a cornerstone
of TB vaccine development is to overcome this delay and recruit
T cells for direct contact with infected lung phagocytes to control
early bacterial growth.5,6 Mtb-speciﬁc vaccine-induced memory
Th17 responses have been associated with accelerated Mtb-
speciﬁc CD4 T cell lung recruitment after Mtb-infection and
improved protection in mice.7 In addition to circulating central
memory T cells (Tcm) and effector memory T cells (Tem), tissue-
localized resident memory T cells (Trm) have also shown the
capacity to increase the adaptive immune reaction to several
pathogens and improve control of infection.8–10 In this regard,
developing vaccine delivery systems to increase lung-localized
Mtb-speciﬁc T cells has been an emerging strategy, including
mucosal delivery of vaccines.9,11–14 While mucosal delivery of the
only currently licensed TB vaccine, BCG, has shown varied results
when given in the airways,15–19 a recent study suggests that Trm
induced by airway delivery of BCG can mediate protection against
Mtb challenge.20
The anti-tuberculosis subunit vaccine H56 is a fusion protein of
Mtb antigens Ag85B, ESAT-6, and Rv2660c.21 When combined
with the liposome-adjuvant CAF01 and given parenterally, H56:
CAF01 elicits a polyfunctional Th1/Th17 CD4 T cell response and
results in an early CD4 T cell response into Mtb-infected lung
tissue and a signiﬁcant reduction in CFU.21–24 Additional studies
using a CAF01-adjuvanted Group A Streptococcus antigen have
shown that an immunization strategy comprising parenteral
priming followed by intranasal mucosal boosting results in the
development of lung-localized T cells with an enhanced recall
response to antigen in the airways.25 Here, we investigate utilizing
this parenteral-priming mucosal-boosting strategy for the delivery
of H56:CAF01. We hypothesized that this strategy will elicit an
Mtb-speciﬁc lung-localized memory T cell population, further
enhance an effective early anti-Mtb T cell response within the lung
after initial Mtb exposure, and improve control of pulmonary Mtb
infection. We found that subcutaneous immunization with H56:
CAF01 followed by an intranasal boost, elicited a population of
long-lived lung-resident Trm and an enhanced early lung T cell
response to aerosol Mtb challenge. However, the T helper
phenotype of the responding CD4 T cells was unaltered by airway
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mucosal boosting and there was not a durable improvement in
control of infection beyond H56:CAF01 given only subcutaneously.
RESULTS
Mucosal boosting with H56:CAF01 induces long-lived lung-
localized Trm
Similar to previous studies using parenteral H56:CAF01 vaccina-
tion,21,22 CB6F1 mice were immunized subcutaneously (s.c.) three
times at 2-week intervals. To compare the relative capacity of
parenteral immunization to a parenteral-mucosal prime-boost
strategy, the third immunization was given intranasally (i.n.) in a
cohort of mice. After vaccination, lung tissue-localized CD4 T cells
were assessed by ﬂow cytometry, utilizing intravenous (IV) anti-
CD45 antibody (Ab) staining to distinguish vasculature-localized
(IV+) cells from lung parenchyma tissue-localized (IV−) leukocytes
localized within lung interstitium/airways,22,26 and vaccine-
speciﬁcity by Th1/17 cytokine production via intracellular staining
(ICS) following ex vivo H56 protein restimulation (Fig. 1a) or
staining with I-Ab: ESAT4-17 tetramer (Fig. 1b). Six weeks after
vaccination, mice receiving 2× s.c. followed by 1× i.n. immuniza-
tions with H56:CAF01 (sc–sc–in; “prime-boost”) resulted in a
signiﬁcantly higher number of lung parenchyma-localized vac-
cine-speciﬁc CD4 T cells than either parenteral-only (3× s.c.) or
mucosal only (3× i.n.) immunized mice (Fig. 1a, b). These lung-
localized CD4 T cells were phenotypically distinct from their
circulating (IV+) counterparts, displaying a lack of central homing
marker CD62L expression, increased amounts of principal Trm
markers CD69 and CD127, as well as the chemokine receptor
CXCR3, and reduced expression of KLRG1 (Fig. 1c).20,27,28 Lung-
localized vaccine-speciﬁc T cells are highly expanded 2 weeks post
i.n. boost, followed by a contraction phase, after which the
number of vaccine-induced lung-localized cells remained rela-
tively stable from 6 weeks until at least 21 weeks post-vaccination
(Fig. 1d, e). The Th1/17 cytokine proﬁle of lung-localized cells was
similar between the vaccinated groups, consisting of multi-
functional Th1 and Th17 cells (Supplemental Figure 1). Addition-
ally, as expected, H56:CAF01 did not prime a vaccine-speciﬁc CD8
T cell response21,22,29 after s.c. or i.n. immunization (data not
shown). Thus, mucosal boosting of s.c. H56:CAF01 induces long-
lived lung tissue-resident CD4 T cells with Trm characteristics that
are maintained in the absence of local antigen stimulus,
suggesting they are bona ﬁde resident memory T cells.
H56:CAF01 prime-pull enhances the magnitude of the early T cell
response against aerosol Mtb infection
To determine if mucosal boosting improved the local lung T cell
response to pulmonary Mtb infection, mice were rested 6 weeks
after vaccination, to allow for the contraction of the adaptive
response, and then given a low dose aerosol Mtb challenge.
As would be expected, 21 days after Mtb challenge, immuno-
histochemical analysis showed that H56:CAF01 vaccination
Fig. 1 Airway mucosal boosting of parenteral H56:CAF01 induces long-lived lung-localized Trm cells. CB6F1 mice were immunized 3 times at
2-week intervals via 3× s.c., 3× i.n., or 2× s.c.+ 1× i.n. (sc–sc–in) routes. T cell populations in the lung parenchyma were assessed following
in vivo intravenous staining to discriminate parenchyma tissue-localized and vasculature-localized circulating cells. a, b Sample FACS plots of
individual mice (left) and compiled bar graphs (n= 3–5/group) of the number of a IV− lung CD4 T cells expressing IFNγ (left) or any of IFNγ/
TNF-α/IL-2/IL-17 cytokines (right, bar graph) after ex vivo H56 restimulation (by ICS), and b IV− lung CD4 CD44hi T cells positive for I-Ab:ESAT-
64–17 tetramer staining, 6 weeks after the ﬁnal immunization. c Surface marker expression of IV− “parenchyma” (solid line) and IV+
“circulating” (dotted line) tetramer+ CD4 lung T cells, and Tet+ IV− FMO staining controls (ﬁlled gray) concatenated from sc–sc–in H56:CAF01
mice from (b). d, e The number of vaccine-speciﬁc IV− lung CD4 T cells determined by d any cytokine+ after H56-restimulation and e I-Ab:
ESAT-64–17 tetramer staining at 2, 6, and 21 weeks post ﬁnal immunization. Bar/symbol, mean ± SEM. *p < 0.05, **p < 0.01 ANOVA with Tukey’s
posttest of log-transformed data
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signiﬁcantly increased pulmonary peri-airway CD4+ lymphocyte
numbers, compared to unvaccinated controls (Fig. 2a–f). Mice that
received the vaccine by either protocol (3× s.c. or sc–sc–in) had a
similar number, size, and distribution (peri-airway/perivascular) of
lymphocyte foci, with indistinguishable CD4+ cell inﬁltration at
this time point (Fig. 2a–f). In contrast, comparison of lung tissue at
earlier time points post Mtb infection revealed that mucosal H56:
CAF01 boosting enhanced the number of distinguishable
pulmonary peri-airway lymphocyte inﬁltrates containing CD4+
cells as early as 8 days after Mtb challenge (Fig. 2g, h). By 13 days
post challenge, the CD4+ cellular response was further ampliﬁed
in the mucosal H56:CAF01-immunized mice (Fig. 2i, j). CD4 cell
staining in both H56:CAF01-immunized groups at all time points
showed similar proportions of CD4 T cells localizing perivascularly,
as is typically seen in response to aerosol Mtb challenge in
resistant mouse strains.30
Overall, sc–sc–in H56:CAF01 mice had enhanced lympho-
cyte activity with greater CD4 T cell inﬁltrate around the
airways, compared to 3× s.c. H56:CAF01 mice during the ﬁrst
2 weeks after Mtb challenge. However, by 3 weeks post
infection the 3× s.c. mice had “caught up” so that at this time
point the overall lymphocytic, and in particular the CD4
lymphocyte, responses were indistinguishable between the
vaccinated animals.
Consistent with previous reports, Mtb-speciﬁc lung T cells did
not enter the lungs of unimmunized mice until 14–21 days post
infection (Fig. 3a).4,22 In contrast, pre-existing Mtb-speciﬁc lung
T cells in 3× s.c. H56:CAF01-vaccinated animals had already
increased in numbers by 8 days after challenge. Notably, at these
earliest time points, sc–sc–in H56:CAF01-immunized mice dis-
played a further enhanced early lung tissue-localized T cell
response, with a >20-fold increased number of Mtb(H56)-speciﬁc
lung CD4 T cells, compared to 3× s.c.-immunized mice, 8 days
after challenge (Fig. 3a). This relatively enhanced vaccine T cell
response was transient, and lung-localized vaccine-speciﬁc T cell
numbers were indistinguishable between vaccinated groups by
2–3 weeks after challenge (Fig. 3a).
Overall, intranasal mucosal boosting of parenteral H56:
CAF01 signiﬁcantly increased the recruitment/expansion of the
lung-localized CD4 T cell response to pulmonary Mtb challenge.
H56:CAF01 prime-pull does not alter the cytokine proﬁle of the
lung CD4 T cells responding to aerosol Mtb infection
As mucosal immunization is often associated with an increase in
Th17-skewed responses, we evaluated the cytokine proﬁle of the
responding cells in the lungs of H56:CAF01-immunized animals
after Mtb challenge. We analyzed IV− lung CD4 T cell expression
of Th1 and Th17 cytokines upon ex vivo H56 restimulation at 3
Fig. 2 Mucosal H56:CAF01 boosting enhances early CD4 T cell responses in the lung. Following low dose aerosol Mtb challenge, immunized
mice were evaluated by immunohistochemistry (IHC) for CD4 lymphocyte responses with the lungs: a–f 21 days after Mtb challenge, lungs of
3× s.c. (b, e) and sc–sc–in (c, f) immunized mice contain larger numbers of brown staining CD4 within peri-airway lymphoid (darker blue)
accumulations than do controls (a, d). Scale bar a–c= 500 μm, scale bar d–f= 200 μm. g, h 8 days and i, j 13 days post Mtb, peri-airway
lymphoid accumulations containing CD4 lymphocytes (brown staining cells) are larger and more widely distributed in sc–sc–in (h, j) relative to
3× s.c. (g, i) immunized mice. Scale bar g–j= 500 μm
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and 6 weeks post Mtb challenge. As expected, we found that the
H56:CAF01 immunization altered the immune proﬁle of respond-
ing lung CD4 T cells towards increased IL-2- and IL-17-expressing
cells (Fig. 3b).22,31 However, there was no difference in cytokine
proﬁle between 3× s.c. and sc–sc–in H56:CAF01-immunized mice,
and further combinatorial Boolean analysis revealed a very similar
pattern of enhanced polyfunctional CD4 T cells in both vaccinated
groups (Fig. 3c). This was true at both the very early time point
after challenge (day 8) when the number of lung H56-speciﬁc CD4
T cells was enhanced in the mucosal-boosted mice (data not
shown), as well as at days 21 and 42 post infection, when the
number was comparable between the H56:CAF01-immunized
groups (Fig. 3). Therefore, airway mucosal boosting with H56:
CAF01 did not skew the Th1/17 proﬁle established by parenteral
H56:CAF01 administration.
Mucosal boosting of H56:CAF01 does not enhance robust
protection against aerosol Mtb
Consistent with previous studies, parenteral immunization with
H56:CAF01 conferred signiﬁcant protection against aerosol Mtb
challenge with a reduction in lung bacterial burden of >1 log in
the standard mouse challenge model (Fig. 4a, b; refs. 21,23,24,32).
Fig. 3 Mucosal H56:CAF01 boosting enhances the magnitude, but
not phenotype, of the early vaccine CD4 T cell response to
pulmonary Mtb infection. CB6F1 mice were rested 6 weeks after
vaccination and challenged with a low dose of aerosolized Mtb. a
The number of H56-speciﬁc CD4 T cells in lung parenchyma (IV−) by
ICS for expression of any of the cytokines IFNγ/TNF-α/IL-2/IL-17 over
the course of infection. b The proportion of H56-speciﬁc cells from
(a) expressing each individual cytokine is shown for 3 weeks (left)
and 6 weeks (right) after Mtb challenge. c Combinatorial Boolean
analysis of H56 lung CD4 T cells (from (b)) at 3 weeks post Mtb
challenge are shown. Bar/symbol, mean ± SD. *p < 0.05, **p < 0.01 vs.
Ctrl or as indicated via ANOVA with Tukey’s posttest of log-
transformed data (a) or raw percentage (b)
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However, contrary to our hypothesis, mucosal boosting of H56:
CAF01 did not further reduce the lung bacterial burden after
aerosol Mtb challenge (Fig. 4b). Though there was trend for a
slight reduction (~0.25 log) in the lung CFU at 3 weeks post
challenge in mucosally boosted mice, which was consistent across
three independent experiments (Fig. 4c), this was transient and no
improved protection was observed at later time points (Fig. 4b).
Still, to better assess the impact of adaptive Trm-mediated
improved protection, without potential confounding local innate
immune changes in the lung environment, vaccinated mice were
rested 21–24 weeks, when vaccine-speciﬁc lung Trm were still
readily detectable (Fig. 1d, e), before low dose Mtb challenged
(see Fig. 4a). In two independent experiments, both vaccinated
groups controlled Mtb infection over non-vaccinated control (>1
log CFU reduction in the lung), conﬁrming the long-term
protective capacity of H56:CAF01 (Fig. 4d).24 However, mucosal
boosting of s.c. H56:CAF01 did not confer additional control of
pulmonary Mtb, nor disseminated Mtb in spleen (Fig. 4d and
Supplemental Figure 1).
To further assess infectious conditions in which mucosal
boosting and an enhanced early lung tissue-localized T cell
response might signiﬁcantly improve control of Mtb-infection, we
considered an extremely low dose challenge model, where as few
as possible bacteria capable of causing a productive infection is
utilized, and which may better mimic natural infection.33 By
reducing the infectious dose, we were able to deliver ~0–40 CFU
into the lungs of infected mice (as assessed from whole lungs
1 day after infection), with productive infection of ~75% of
exposed mice (the other 25% being stochastically uninfected). In
this setting, we observed a similar ﬁnding as seen with a 50–150
CFU infecting dose; that mucosal boosting resulted in a transient
reduction in lung CFU in the pre-peak phase of infection (3 weeks),
but no improved protection during the chronic stage of infection
(Fig. 4e).
Given the inability of mucosal boosting of H56:CAF01 to
signiﬁcantly improve protection over parenteral vaccination alone,
we next wished to modify the immunization/infection settings to
maximize the potential protective effect of pre-existing lung-
localized anti-Mtb T cells. In one setting, we added a second i.n.
H56:CAF01 boost to sc–sc–in mice (sc–sc–in→in) just 10 days
before ultra-low dose Mtb challenge. As hypothesized, this second
i.n. boost did indeed further increase the lung-localized T cell
response by 9.4-fold over the sc–sc–in regiment at the time of
infection (Fig. 5a). However, despite a now >2500-fold increase in
H56-speciﬁc lung T cells at the time of challenge, sc–sc–in→ in
H56:CAF01-immunized mice displayed no further reduction in
lung CFU over 3x s.c.-immunized mice (Fig. 5b). Furthermore,
vaccination did not inhibit productive Mtb infection, as the
proportion of animals with detectable bacteria 3 weeks post ultra-
low dose Mtb challenge in 3× s.c. (13/16, 81%), sc–sc–in (13/16,
81%), or sc–sc–in→in (15/16, 94%) H56:CAF01-immunized mice
was not lower than that of control mice (6/8, 75%).
In another setting, we sought to isolate the protective capacity
of the lung-localized Trm by inhibiting the recruitment of
circulating Tcm/Tem following Mtb challenge. We treated control
and immunized mice with FTY720 during the entire ﬁrst 3 weeks
of Mtb infection. FTY720 inhibits S1P1-mediated cell migration
into efferent lymphatics resulting in inhibited recruitment of cells
from secondary lymphoid organs into inﬂamed tissue. FTY720-
treated mice were conﬁrmed to have the expected lack of
circulating naïve CD4 T cells throughout the experiment (Supple-
mental Figure 3). We hypothesized that FTY720 would inhibit the
early lung T cell response in 3× s.c. H56:CAF01-immunized-mice,
but not in mice that received a mucosal boost, in which the pre-
existing lung Trm would compensate for deﬁcient T cell
recruitment and better control the lung infection. Day 8 after
Mtb challenge, we conﬁrmed that FTY720-treatment reduced the
lung-localized (IV−) H56-speciﬁc T cell response in 3× s.c., but not
in sc–sc–in, H56:CAF01-immunized mice (Fig. 5c). As expected,
FTY720 treatment inhibited control of Mtb infection (Fig. 5d). Still,
3× s.c. H56:CAF01 was protective under FTY720 treatment, with
~1 log lung CFU reduction versus unvaccinated treated mice
(Fig. 5d). However, FTY720 treatment did not reveal a speciﬁc
protective role of Trm in mucosal-boosted H56:CAF01 sc–sc–in
vaccinated mice, where lung bacterial burden was not different
from 3× s.c. H56:CAF01-vaccinated mice (Fig. 5d).
Taken together, these data support that the enhanced pre-
existing Trm population and resultant early lung-localized T cell
response elicited by mucosal-boosted H56:CAF01-immunized
mice does not readily contribute to improved control of
pulmonary Mtb infection.
In our studies in which aerosol Mtb challenge was given
6 weeks (but not 20+ weeks) after immunization, we noted a
trend of transient improved vaccine protective after mucosal
boosting that was statistically signiﬁcant in the ultra-low dose
setting. Therefore we considered if innate differences in the lung
environment after i.n. boosting could be contributing to increased
or decreased Mtb control in our system, such as has been reported
in other settings.34 At 6 weeks post-vaccination, the number and
activation state (assessed via CD86 and MHC II surface expression)
of lung macrophages in H56:CAF01 3× s.c. and sc–sc–in
immunized mice were not different from each other, or controls
(Fig. 6a–c). Furthermore, after aerosol Mtb challenge, the
activation stated of alveolar macrophages remained comparable
between the 3× s.c. and sc–sc–in immunized mice (Fig. 6d, e).
Moreover, the cytokine environment of the lungs in response to
Mtb infection, including pro-inﬂammatory cytokines (e.g., IFNγ, IL-
1β, IL-6, and IL-12) and Mtb-permissive cytokines (such as IL-5 and
IL-10), and type I interferons were not different between 3× s.c.
and sc–sc–in immunized mice (Fig. 6f). In contrast, mice that
received a mucosal H56:CAF01 boost 10 days prior to challenge
(sc–sc–in→in) had signiﬁcantly increased number and activation
state of lung macrophages prior to Mtb challenge (Fig. 6a–c). Early
after Mtb challenge, sc–sc–in→ in immunized mice also showed
increased activation of alveolar macrophages and increased IL-
12p70 and IL-6 in the lung (Fig. 6d, f). However, this increased
macrophage activation was notably not associated with improve
protection (Fig. 5b). Overall, alteration of the innate immune
environment by mucosal H56:CAF01 appeared to be nominal in
our challenge studies comparing 3× s.c. and sc–sc–in immuniza-
tions, especially after a sufﬁcient post-immunization resting
period.
Intranasal boosting enhances early lung T cell response with
limited impact on protection in susceptible mouse strains
The CB6F1 mouse strain is relatively resistant to aerosol Mtb
infection, with a prolonged period of asymptomatic chronic/latent
tuberculosis. In contrast, other inbred strains display increased
Fig. 4 Mucosal H56:CAF01 boosting does not provide improved
stable protection against aerosol Mtb challenge. a Experimental
design of efﬁcacy studies in CB6F1 mice, with varied lengths of post-
vaccination rest periods and dose of aerosol Mtb used for challenge
that are represented in this ﬁgure (b–e). b Total lung CFU after low
dose aerosol Mtb infection, compiled from three independent
experiments with 4–8 mice/time point challenged with the same
dose of Mtb. c Total lung CFU at 3 weeks after Mtb challenge from
three independent experiments compiled in (b). d Total lung CFU
from two independent experiments assessed 3 weeks after low dose
Mtb challenge of 21–24 weeks rested immunized mice. e Total lung
CFU assessed 3 weeks post ultra low dose aerosol Mtb challenge,
representative of 2 experiments with similar results. Bar/line, mean
± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. Ctrl or as indicated via
ANOVA with Tukey’s posttest of log-transformed data. ns not
signiﬁcant. Dots on bars represent individual mice
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T. . .
JS Woodworth et al.
820
Mucosal Immunology (2019) 12:816 – 826
susceptibility to aerosol Mtb challenge. Therefore, we investigated
if an intranasal boosting regiment would signiﬁcantly increase or
otherwise alter the lung-localized T cell response and control of
Mtb infection in strains with genetic susceptibility to infection.
129S2 mice are highly-susceptible to Mtb infection due to a
negative effect of increased type I IFN on lung phagocyte
recruitment following aerosol challenge.35 Similar to results in
CB6F1 mice, subcutaneous H56:CAF01 vaccination improved
control of low dose aerosol Mtb infection in 129S2 mice, while
mucosal H56:CAF01 boosting did not further improve pulmonary
Mtb control (Fig. 7a). Mucosal H56:CAF01 boosting did increase
the early (day 8) lung-localized vaccine T cell response to Mtb
challenge (Fig. 7b). However, as in CB6F1 mice, there was no effect
on the phenotype of the responding CD4 T cells. Lung-localized
H56-speciﬁc CD4 T cells in the Mtb-infected lungs of H56:CAF01-
vaccinated mice had the same Th1/17 cytokine proﬁles, with
enhanced IL-2 and IL-17 expression (Fig. 7c) and relative T-bet/
RORyT expression proﬁles (Fig. 7d) regardless of route of
vaccination.
C3H is another mouse strain highly-susceptible to Mtb
infection.36 Dissemination of Mtb from the lungs is greatly
delayed in these mice, and this is associated with a delayed
initiation of adaptive cellular immune response (relative to B6
mice).37 Similar to 129 Sv and CB6F1 mice, subcutaneous H56:
CAF01 vaccination of C3H mice provided signiﬁcant protection
against low dose aerosol Mtb challenged C3H mice, compared to
unvaccinated controls (Fig. 7e). Mucosal boosting with H56:CAF01
also greatly increased (>40-fold) the early lung-localized vaccine T
cell response to pulmonary Mtb challenge (Fig. 7f) over 3× s.c.
H56:CAF01-vaccinated mice, but did not provide additional
protection (Fig. 7e). Notably, as in the other two mouse strains,
mucosal boosting also did not alter Th1/17 proﬁle of the
responding lung-localized vaccine CD4 T cells (Fig. 7g).
Overall, the results in the susceptible mouse strains were very
similar to those of the resistant strain; despite an increased lung T
cell response, no change in vaccine-speciﬁc T cell proﬁle nor
addition protection was conferred by mucosal boosting of s.c.
H56:CAF01 immunization.
DISCUSSION
We have conﬁrmed and expanded previous ﬁndings that
parenteral vaccination with H56:CAF01 induces a combined Th1/
Th17 population of memory T cells that accelerates the T cell
response to aerosol Mtb challenge and improves control of
infection.21,22,24 We further report that boosting H56:CAF01
parenteral immunization with an intranasal boost results in the
induction of a population long-lived lung-localize Trm and
enhances the early vaccine T cell response within lymphocytic
foci in the lungs following aerosol Mtb infection. However, we
were surprised to ﬁnd that this pre-existing lung T cell population
and the resultant robust increase in the early lung T cell response
did not improve protection against aerosol Mtb challenge. These
data suggest practical limitations on the ability of vaccine-elicited
T cells to control aerosol Mtb infection.
There is growing recognition that Trm, non-circulating T cells
that reside within tissue parenchyma after infection, can provide
secondary immune protection in various settings.28 Parabiosis
studies remain the gold-standard in conﬁrming true tissue-
resident status of a given T cell. However, phenotypic character-
ization of Trm has also begun to identify biological markers, and,
when performed in combination with in vivo intravenous
staining,26 the identiﬁcation of tissue-localized Trm via ﬂow
cytometry has greatly advanced. We report that the lung-
localized CD4 T cells enhanced after airway mucosal boosting of
parenteral H56:CAF01 display many characteristics of true Trm.
Fig. 5 Lung-localized Trm elicited by H56:CAF01 airway boosting do not improve control of pulmonary Mtb infection. a, b CB6F1 mice were
vaccinated 3–4 times with H56:CAF01, as indicated, and assessed for a total number of H56-speciﬁc lung-localized (IV−) CD4 T cells 6 weeks
after the third vaccination (n= 5 mice/group), and b total lung CFU 3 weeks after low dose Mtb aerosol challenge. c, d In a separate single
experiment, CB6F1 mice were vaccinated with H56:CAF01 as indicated, rested 6 weeks, and challenged with low dose aerosol Mtb. One day
prior to challenge some mice began and continued to receive FTY720 (FTY). c The total number of lung-localized H56-speciﬁc CD4 T cells was
assessed 8 days following Mtb challenge in mice treated/non-treated with FTY720 (n= 5 mice/group). d Total lung CFU 3 weeks post
challenge of control and vaccinated mice receiving FTY720-treatment. Bar, mean ± SEM, dots represent individual mice. *p < 0.05, **p < 0.01,
****p < 0.0001 vs. Ctrl or as indicated via ANOVA with Tukey’s posttest of log-transformed data. ns not signiﬁcant
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IV-staining shows that these T cells are located within the lung
tissue and display the canonical Trm phenotype of CD62L− CD69
+, which functionally associates with tissue retention, as well as
displaying a CD127+ CXCR3+ KLRG1 phenotype which has also
been associated with Trm (Fig. 1).20,27,28 Moreover, while
quantitative histology shows that insufﬁcient liberation from
tissue results in a woeful under-counting by ﬂow cytometry, we
were able to readily detect these cells after vaccination. Most
importantly, the H56-speciﬁc T cells were detected in the lung
tissue as late as 21 weeks after immunization in mice, functionally
conﬁrming their long-lived lung-localized memory Trm
phenotype.
Given that mucosal boosting enhanced lung Trm and the very
early lung-localized T cell response to aerosol Mtb challenge, it
was somewhat surprising that this did not translate into improved
protection beyond s.c.-only H56:CAF01 immunization. Indeed, a
recent study showed that overcoming the delayed accumulation
of vaccine-elicited CD4 T cells into the lungs, by intratracheal
delivery of activated Mtb antigen-loaded dendritic cells, greatly
improved Mtb control.38 One possible explanation for the lack of
improved control is that while the enhanced Trm accelerated the
vaccine response kinetics, the early T cells were unable to target
the appropriate cells necessary to control infection. Mtb is known
to actively prevent antigen presentation and activation of infected
cells, which could have real implications for what a T cell vaccine
can effectively achieve in vivo.39,40 This leads to a model in which
infected cells are severely limited in their ability to generate an
effective cognate interaction with vaccine-elicited T cells at the
site of infection within the ﬁrst weeks of Mtb infection41 and
suggests limitations of a vaccination approach that depends upon
tissue-localized T cells as a ﬁrst line of defense against infected
cells at the site of pulmonary infection. Our combined ﬂow
cytometry and histological data conﬁrms that while mucosal H56:
CAF01 boosting further enhanced the CD4 T cell response in the
lungs within the ﬁrst 2 weeks post infection, this did not enhance
Mtb control. During these ﬁrst 2 weeks, CD4 T cells in mucosally
boosted mice were localized into peri-airway/perivascular foci
with a similar distribution to that seen in all H56:CAF01-vaccinated
mice at later time points. This suggests that the cells were
anatomically situated to confer protection, and were therefore
otherwise deﬁcient in their capacity to do so. Notably, even further
expansion of this early Trm-mediated response by >10-fold using
an addition i.n. boost prior to challenge was also ineffective
towards improving protection over 3× s.c. H56:CAF01-immunized
mice (Fig. 5). Furthermore, isolating the Trm-mediate protection
by blocking Tcm/Tem recruitment via FTY720 treatment demon-
strated that the expanded Trm population in i.n.-boosted mice did
not improve protection against Mtb challenge (Fig. 5). Together,
Fig. 6 Innate inﬂammatory environment in the lungs of H56:CAF01-immunized mice. The total number of a lung interstitial tissue
macrophages (IV−, CD11b+, CD11c−, Ly6G−) and b alveolar macrophages (CD11chi, CD11bmid, CD103−, autoﬂuorescent) were enumerated by
ﬂow cytometry 6 weeks after the third immunization, and c the relative surface expression of CD86 and MHC-II on alveolar macrophages
assessed and expressed as geometric mean ﬂuorescent intensity. d, e CD86 and MHC-II surface expression on alveolar macrophages d 8 days
and e 21 days after ultra-low dose aerosol Mtb infection. f Lung cytokine levels 8 days post Mtb challenge. Ctrl, [gray bars]; H56:CAF01 (via 3×
s.c. [open bars] or sc–sc–in routes [solid bars]); sc–sc–in immunized mice given a second i.n. boost 10 days prior to challenge (sc–sc–in–in,
[checkered bars]). Bars, mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. Ctrl or as indicated, determined by one-way ANOVA with Tukey’s
posttest. Data are representative of two independent experiments with similar results
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these data support the interpretation that the Trm-mediated
response itself cannot provide additional Mtb control in this
setting. Here, it is worth noting that, 3× s.c. H56:CAF01 itself did
induce a small, but detectable, long-lasting lung-localized T cell
population in immunized mice with Trm markers (Fig. 1, data not
shown and ref. 22) and that likely conferred protection in the
presence of FTY720. It is possible that this small population alone
conferred some tissue-localized protection, which further expan-
sion of this population by mucosal boosting did not enhance.
Airway vaccination with other anti-Mtb vaccines has shown
promise in other settings. Lung-resident CD4+ memory T cells
induced after pulmonary immunization with an anti-Mtb recom-
binant inﬂuenza virus vaccine are associated with protection in
mice.42 Intranasal immunization with BCG further improves Mtb
control in mice in several, but not all, studies,15–19 and clinical
development of aerosolized BCG delivery is ongoing.43 While a
mechanistic interpretation of such improved protection after
pulmonary BCG infection must be carefully considered due to
non-speciﬁc effects, one study suggests that the protection is CD8
Trm-dependent.20 Intranasal delivery of recombinant adenovirus
Mtb-vaccine is more protective than parenteral immunization,
although here the natural respiratory mucosa tropism of the
adenoviral vector leading to increased magnitude of vaccine take
is likely a factor.44,45 In contrast, intranasal boosting of recombi-
nant adenovirus with a recombinant vesicular stomatitis virus
(VSV) resulted in reduce T cell-mediated control of Mtb via a type I
interferon-mediated inhibition of the lung macrophage inﬂam-
matory response, including reduced activation in vivo after Mtb
infection.34 Notably, in our studies, the activation status of the
alveolar macrophages in response to aerosol Mtb challenge was
not diminished by i.n. administration of H56:CAF01 (Fig. 6),
indicating that a mucosal vaccine-induced reduction of macro-
phage capacity was not the reason that the enhanced early T cell
response in sc–sc–in H56:CAF01-immunized mice was unable to
further improve control of Mtb. To the contrary, mice that received
a second i.n. administration of H56:CAF01 (sc–sc–in→ in) displayed
increased activation of alveolar macrophages and increased lung
IL-12 after Mtb challenge, suggesting that (initially) after H56:
CAF01 i.n. boosting the innate lung environment is pro-
inﬂammatory. However, by 6 weeks post-vaccination, the basal
lung environment and subsequent macrophage response to
aerosol Mtb challenge was not different between control, 3× s.c.
Fig. 7 Mucosal H56:CAF01 boost elicits early lung-localized T cell responses without additional protection in susceptible mouse strains. 129S2
(a–d) and C3H (e–g) mice were rested 6 weeks after vaccination and aerosol challenged with low-dose Mtb. Post challenge, lungs were
assessed for (a, e) total CFU, and (b, f) the total number of H56-speciﬁc CD4 T cells in lung parenchyma (IV-) by ICS for expression of any of the
cytokines IFNγ/TNF-α/IL- 2/IL-17. (c, g) The proportion of H56-speciﬁc cells from (b, f, respectively) expressing each an individual cytokine is
shown for 3 weeks after Mtb challenge. (d) The proportion of I-Ab:ESAT-64-17 tetramer+ lung IVCD4 T cells expressing the indicated
transcription factor. Symbol, mean±SEM of n= 8 (a, e) n= 4 (b, f) mice. Bar, mean±SD of n= 4 mice. *p < 0.05, **p < 0.01 vs. Ctrl or as indicated,
via ANOVA with Tukey’s post-test of log-transformed data (a, b, e, f) or raw percentages (c, d, g). ns not signiﬁcant
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T. . .
JS Woodworth et al.
823
Mucosal Immunology (2019) 12:816 – 826
and sc–sc–in H56:CAF01-immunized mice, demonstrating that our
experimental design using an adjuvanted subunit vaccine and
sufﬁciently long resting periods mitigated such transient effects of
mucosal immunization.
Recently, i.n. immunization with a recombinant Mtb antigen
fusion protein combined with a cyclic dinucleotide adjuvant was
demonstrated to be more protective than subcutaneous immu-
nization.46 Notably, this enhanced protection was associated with
Th17-skewing of the immune response after i.n. immunization and
the resultant combined Th1+ Th17 vaccine proﬁle.46 Likewise, i.n.
immunization with another protein subunit vaccine in a Th1-
skewing adjuvant, ID93:GLA-SE, also resulted in a dramatically
Th17-skewed T cell response.47 Similarly, i.n. BCG induces a Th17
immune response that confers protection in the DBA/2 mouse
model of TB where s.c. BCG, which does not induce Th17
immunity, is not protective.48 Moreover, increasing the Th17
response to parenteral BCG immunization, via blocking IL-10
during vaccination, or i.n. BCG by adjuvanting with cholera toxin
further improves control of Mtb infection.19,49 Indeed, in
combination with anti-Mtb Th1 cells, vaccine-elicited Th17 cells
accelerate vaccine immunity and are protective against Mtb
infection.7 Taken together, these observations suggest that in
many cases, the improved protection after airway mucosal
immunization is provided not by enhancing a vaccine-elicited
Trm population, but by skewing the vaccine-induced Th1
response into a Th1+ Th17 response. When given parenterally,
H56:CAF01 already elicits a Th1+ Th17 anti-Mtb response, which
is not altered by mucosal boosting (Figs. 3 and 6). This pre-existing
vaccine-induced Th1+ Th17 proﬁle of s.c. H56:CAF01 may well
explain why, in contrast to BCG and other anti-Mtb subunit
vaccines, mucosal boosting of parenteral s.c. H56:CAF01 did not
enhance protection.
Improved efﬁcacy of a vaccine-elicited Th1 response by addition
of a Th17 response is likely pathogen speciﬁc. Indeed, in a set of
studies comparing adjuvant impact on vaccine immunogenicity
and efﬁcacy, H56, was most protective against Mtb infection when
it was combined with the Th1+ Th17-skewing CAF01 adjuvant.23
In contrast, the efﬁcacies of both an anti-chlamydia and an anti-
inﬂuenza vaccine did not correlate with adjuvant-dependent Th17
responses.23 In Mtb infection, Th17 cells have been associated
with acceleration of the initial response to Mtb challenge and
organization of cells within a protective granuloma structure to
provide long-term control.7,50,51
Over the past two decades, various T cell populations with
different targets and functionalities have been identiﬁed as being
protective against Mtb. Finding the optimal combination of
complementary T cells to be induced by a vaccine against Mtb
is still a mystery. Certainly, even the idea that there is one such
combination is likely an oversimpliﬁcation of the task at hand.
Early T cell responses elicited by vaccination against Mtb are
protective, but have inherent limits in the course of Mtb infection.
Aerosol delivery of vaccines to maximize Trm responses is
intriguing, but the impact on increased and true vaccine-
memory protection may be vaccine dependent. The ability for
airway route of vaccination to show improvement over parenteral
vaccination may depend on the speciﬁc vaccine used and the
population to be vaccinated for protection (e.g., genetic suscept-
ibility, Mtb exposure-level of the environment). Different vaccine
candidates may be “lacking” different T cell subsets for their
optimization. Here, we show that in the case of parenteral H56:
CAF01, expanding the lung-localized population of Trm does not
complement the existing vaccine-elicited protective CD4 T cells.
METHODS
Mice
Six-to-eight-week-old female C3H/HeNHsd and CB6F1 (BALB/c ×
C57BL/6) (Envigo, Netherlands), and 129S2PasCrl (Charles River,
Germany) mice were housed at Statens Serum Institut and rested
1 week before any procedures. All handling and procedures were
performed in compliance with the European Community Directive
86/609 for the care and use of laboratory animals.
Immunizations
Mice were immunized three times at 2-week intervals. Subcuta-
neous (s.c.) immunizations comprised 200 μl of CAF01 (250 μg
DDA/50 μg TDB) alone (“Ctrl”) or mixed with 5 μg H56 protein,
produced as previously described.23 Intranasal (i.n.) immunizations
comprised 5 μg H56 in CAF01 (0.25–1.0× of s.c. dose) split over 15
μl per nostril.
Mtb infection and lung CFU enumeration
Following immunization, mice were rested 6–20 weeks prior to
aerosol challenge with Mtb. Virulent M. tuberculosis Erdman (TMC
107, ATCC) grown to log-phase in Sauton medium (BD Pharmin-
gen “BD”, San Diego, CA, USA) stored at −80 °C. was suspended in
PBS Tween 20 (0.05%) and aerosolized for inhalation using a
Biaera exposure system controlled via AeroMP software (Biaera,
Hagerstown, MD, USA). Average low dose infection delivered
50–150 CFU/animal and as conﬁrmed by CFU plating of whole
lung homogenates 1 day after infection. For ultra-low dose
infections, 1/5 dose was delivered resulting in productive infection
of ~75% of animals with 0–40 lung CFU at 1 day post infection.
To enumerate lung bacteria, left lung lobes from individual mice
were homogenized using Miltenyi AutoMACS dissociator and M-
tubes (Miltenyi, Germany), serially diluted in PBS, grown for
2 weeks at 37 °C, and CFU enumerated as previously described.21
For ultra low dose infections, mice without a detectable
productive infection (i.e., no CFU detectable, limit of detection
= 6 CFU/lung) were excluded from analyses of changes in
bacterial burden.
Intravenous staining
Anti-CD45.2 FITC (BD), 2.5 μg/mouse was given intravenously via
tail vein 3–6min prior to organ harvest to distinguished
parenchymal-localized (IV−) and vasculature-associated (IV+)
cells.
Tissue preparation and cytokine analysis
Lungs were aseptically removed from euthanized mice into 4 °C
2.5 ml RPMI media, mildly dissociated via AutoMACS (C-tubes,
Miltenyi) and supernatants harvested for cytokine analyses, before
digested for 30–60min with collagenase IV (Sigma-Aldrich) and
forced through a 70 μm ﬁlter and washed twice before direct
staining for MHC II tetramers and surface markers or stimulated for
ICS analysis. Lung and spleens for CFU were frozen at −80 °C until
further use.
Total lung supernatants were assayed for cytokines (IL-1β, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12p70, IFNγ, TNFα, KC/GRO) via a 10-plex
murine V-plex assay (MesoScaleDiagnostic, Rockville, MD, USA)
and for murine type I interferons using individual ELISA kits for
IFNα (eBioscience, San Diego, CA, USA) and IFNβ (PBL Assay
Science, Piscataway, NJ, USA).
Flow cytometry
Intracellular staining (ICS) for cytokines. 1–2 × 106 lung MNCs
were stimulated in vitro in V-bottom 96-well plates at 37 °C in
media containing anti-CD49d (1 μg/ml) and anti-CD28 (1 μg/ml)
without antigen or in the presence of H56 protein at 5 μg/ml for 1
h, plus 6 h in the presence of 10 μg/ml brefeldin A (Sigma-Aldrich),
after which cells were maintained at 4 °C for 2–8 h before staining.
Cells were surface-stained using anti-CD4-allophycocyanin (clone
RM4-5; BD Biosciences; BD) before ﬁxation and permeabilization
using Cytoperm/Cytoﬁx kit (BD) as per manufacturer’s instructions,
and subsequently stained for intracellular cytokines with anti–IFN-
γ PE-Cy7 (XMG1.2; BD), anti–TNF-α-PE (MP6-XT22; BD), IL-2-
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allophycocyanin-Cy7(JES6-5H4; BD), and IL-17A-PerCP-Cy5.5 (I7B7;
eBiosciences, San Diego, CA, USA). Antigen-speciﬁc cell numbers
determined by Nucleocounter (ChemTec, Deerﬁeld Beach, FL,
USA) enumeration in combination with ICS data or by direct event
count enumeration of known sample volumes run by ﬂow
cytometry. Non-speciﬁc background cytokine positive events from
paired non-H56 stimulated were subtracted for each combinator-
ial Boolean gate.
Tetramer and surface staining. I-Ab:ESAT-64-17-APC or PE, and I-A
b:
hCLIP negative control, were provided by the NIH tetramer facility
(Atlanta, GA, USA). When applicable, cells were stained with
tetramers for 30 min at 37 °C before surface staining at 4 °C with
anti-CD4-BV786 (GK1.5; BD), CD44 Alexaﬂour700 (IM7; Biolegend,
San Diego, CA, USA) or BV711 (BD), CD127- PE/CF594 (SB/199; BD),
KLRG1- BV711 (2F1; BD), CXCR3-PerCP/Cy5.5 (CXCR3-173;
eBioscience), and CD69-PE/Cy7 (H1,2F3, BD), CD62L-APC/Cy7
(MEL-4; eBioscience), CD11b-PE/Cy7 (M1/70;BD), CD11c-BV421
(HL3;BD), CD86-BV510 (GL1;BD), I-A/I-E-BV605 (MHC II, M5/
114.15.2;BD), Ly6G-PE (1A8;BD), CD103-BV786 (BD). Dead cells
were excluded by the ﬁxable viability e506 or e780 (eBioscience).
For transcription factor staining, the FoxP3/transcription factor
buffer set (eBioscience) with anti-T-bet-APC (4B10; BD) and anti-
RORγT-PE/CF594 (Q31-378; BD) was used.
Data was collected using a LSR Fortessa (BD) and data analyzed
Flow cytometry analyses including ﬁle concatenation and Boolean
analysis was performed with FlowJo software v.10 (Tree Star,
Ashland, OR, USA).
FTY720 protocol
Mice were given daily oral administration of 70 μg FTY720 (Sigma-
Aldrich) (200 μl, 350 μg/ml) beginning 1 day prior to Mtb
challenge and continuing until organ harvest post infection.
Immunohistochemical staining
Lung tissue was ﬁxed in 4% buffered paraformaldehyde formalin
(VWR, Leuven, Belgium) and stored at 4 °C until further processing
at BioSiteHisto (Helsinki, Finland). Brieﬂy, ﬁxed tissue was
embedded in parafﬁn and sectioned prior hematoxylin and eosin
staining or anti-CD4 antibody staining with immunoperoxidase
detection and hematoxylin counterstaining. Stained sections were
analyzed by an independent and blinded pathologist.
Statistical analysis
Prism software (v.7.04, GraphPad, San Diego, CA) was used to
perform all statistical analyses as described in ﬁgure legends. CFU
data and total cytokine positive cells numbers were log-
transformed to normalize variance before analysis.
ACKNOWLEDGEMENTS
The authors thank Sandra Isling and Ming Olsen for excellent technical help, as well
as the staff at the experimental animal facilities at Statens Serum Institut. The authors
acknowledge the NIH Tetramer Core Facility for the provision of I-Ab:ESAT-64–17 and
corresponding negative control tetramer I-Ab:hCLIP. This work was supported by the
European Commission through the ADITEC consortium contract (FP7-HEALTH-
2011.1.4-4-280873) and the TBVAC2020 Consortium (TBVAC H2020-PHC-2014-2015-
643383), the Lundbeck Foundation (R171-2014-830), and the Danish Research
Council (DFF—1331-00063).
AUTHOR CONTRIBUTIONS
J.S.W., E.M.A., R.M., and P.A. developed the concept and designed the experiments. D.
C. contributed expertise to the immunization strategy and formulations. J.S.W.
performed the experiments and analyzed the results. J.P.C. analyzed the histology
data in a blinded manner. J.S.W. wrote the manuscript with critical input and revision
for intellectual content from P.A. All authors approved of the ﬁnal version.
ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41385-019-0145-5)
contains supplementary material, which is available to authorized users.
Competing interests: P.A. is a co-inventor on patents relating to cationic liposomes
as vaccine adjuvants and to the TB fusion protein Ag85B-ESAT-6-Rv2660c (H56). All
rights have been assigned to the Statens Serum Institut. The other authors declare no
competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Houben, R. M. & Dodd, P. J. The global burden of latent tuberculosis infection: a
re-estimation using mathematical modelling. PLoS Med. 13, e1002152 (2016).
2. Zaman, K. Tuberculosis: a global health problem. J. Health Popul. Nutr. 28,
111–113 (2010).
3. WHO. The End TB Strategy. (World Health Organization, Geneva, Switzerland,
2015).
4. Wolf, A. J. et al. Initiation of the adaptive immune response to Mycobacterium
tuberculosis depends on antigen production in the local lymph node, not the
lungs. J. Exp. Med. 205, 105–115 (2008).
5. Andersen, P. & Woodworth, J. S. Tuberculosis vaccines—rethinking the current
paradigm. Trends Immunol. 35, 387–395 (2014).
6. Srivastava, S. & Ernst, J. D. Cutting edge: direct recognition of infected cells by
CD4 T cells is required for control of intracellular Mycobacterium tuberculosis
in vivo. J. Immunol. 191, 1016–1020 (2013).
7. Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary
CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis
challenge. Nat. Immunol. 8, 369–377 (2007).
8. Zens, K. D., Chen, J. K. & Farber, D. L. Vaccine-generated lung tissue-resident
memory T cells provide heterosubtypic protection to inﬂuenza infection. JCI
Insight 1, e85832 (2016).
9. Muruganandah, V., Sathkumara, H. D., Navarro, S. & Kupz, A. A systematic review:
the role of resident memory T cells in infectious diseases and their relevance for
vaccine development. Front. Immunol. 9, 1574 (2018).
10. Teijaro, J. R. et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate
optimal protection to respiratory virus infection. J. Immunol. 187, 5510–5514
(2011).
11. Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis
vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase
1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939–946
(2014).
12. Darrah, P. A. et al. Aerosol vaccination with AERAS-402 elicits robust cellular
immune responses in the lungs of rhesus macaques but fails to protect against
high-dose Mycobacterium tuberculosis challenge. J. Immunol. 193, 1799–1811
(2014).
13. Reljic, R. et al. Mucosal vaccination against tuberculosis using inert bioparticles.
Infect. Immun. 81, 4071–4080 (2013).
14. Xing, Z. et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine
markedly enhances the protection of BCG-primed guinea pigs against pulmonary
tuberculosis. PLoS ONE 4, e5856 (2009).
15. Chen, L., Wang, J., Zganiacz, A. & Xing, Z. Single intranasal mucosal Myco-
bacterium bovis BCG vaccination confers improved protection compared to
subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72,
238–246 (2004).
16. Aguilo, N. et al. Pulmonary Mycobacterium bovis BCG vaccination confers dose-
dependent superior protection compared to that of subcutaneous vaccination.
Clin. Vaccine Immunol. 21, 594–597 (2014).
17. Derrick, S. C., Kolibab, K., Yang, A. & Morris, S. L. Intranasal administration of
Mycobacterium bovis BCG induces superior protection against aerosol infection
with Mycobacterium tuberculosis in mice. Clin. Vaccine Immunol. 21, 1443–1451
(2014).
18. Palendira, U., Bean, A. G., Feng, C. G. & Britton, W. J. Lymphocyte recruitment and
protective efﬁcacy against pulmonary mycobacterial infection are independent
of the route of prior Mycobacterium bovis BCG immunization. Infect. Immun. 70,
1410–1416 (2002).
19. Grifﬁths, K. L. et al. Cholera toxin enhances vaccine-induced protection
against Mycobacterium tuberculosis challenge in mice. PLoS ONE 8, e78312
(2013).
20. Perdomo, C. et al. Mucosal BCG vaccination induces protective lung-resident
memory T cell populations against tuberculosis. mBio 7, 6 (2016).
21. Aagaard, C. et al. A multistage tuberculosis vaccine that confers efﬁcient pro-
tection before and after exposure. Nat. Med. 17, 189–194 (2011).
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T. . .
JS Woodworth et al.
825
Mucosal Immunology (2019) 12:816 – 826
22. Woodworth, J. S. et al. Subunit vaccine H56/CAF01 induces a population of cir-
culating CD4 T cells that trafﬁc into the Mycobacterium tuberculosis-infected lung.
Mucosal Immunol. 10, 555–564 (2017).
23. Knudsen, N. P. et al. Different human vaccine adjuvants promote distinct antigen-
independent immunological signatures tailored to different pathogens. Sci. Rep.
6, 19570 (2016).
24. Lindenstrom, T. et al. Cells primed by live mycobacteria versus a tuberculosis
subunit vaccine exhibit distinct functional properties. EBioMedicine 27, 27–39
(2018).
25. Christensen, D., Mortensen, R., Rosenkrands, I., Dietrich, J. & Andersen, P. Vaccine-
induced Th17 cells are established as resident memory cells in the lung and
promote local IgA responses. Mucosal Immunol. 10, 260–270 (2017).
26. Anderson, K. G. et al. Intravascular staining for discrimination of vascular and
tissue leukocytes. Nat. Protoc. 9, 209–222 (2014).
27. Mackay, L. K. et al. The developmental pathway for CD103(+)CD8+ tissue-
resident memory T cells of skin. Nat. Immunol. 14, 1294–1301 (2013).
28. Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41,
886–897 (2014).
29. Korsholm, K. S. et al. Induction of CD8+ T-cell responses against subunit antigens
by the novel cationic liposomal CAF09 adjuvant. Vaccine 32, 3927–3935 (2014).
30. Slight, S. R. et al. CXCR5(+) T helper cells mediate protective immunity against
tuberculosis. J. Clin. Invest. 123, 712–726 (2013).
31. Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term pro-
tective immunity characterized by multifunctional CD4 memory T cells. J.
Immunol. 182, 8047–8055 (2009).
32. Billeskov, R., Christensen, J. P., Aagaard, C., Andersen, P. & Dietrich, J. Comparing
adjuvanted h28 and modiﬁed vaccinia virus ankara expressing h28 in a mouse
and a non-human primate tuberculosis model. PLoS ONE 8, e72185 (2013).
33. Sharpe, S. et al. Ultra low dose aerosol challenge with Mycobacterium tuberculosis
leads to divergent outcomes in rhesus and cynomolgus macaques. Tuberculosis
96, 1–12 (2016).
34. Jeyanathan, M. et al. Differentially imprinted innate immunity by mucosal boost
vaccination determines antituberculosis immune protective outcomes, inde-
pendent of T-cell immunity. Mucosal Immunol. 6, 612–625 (2013).
35. Dorhoi, A. et al. Type I IFN signaling triggers immunopathology in tuberculosis-
susceptible mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 44,
2380–2393 (2014).
36. Chackerian, A. A. & Behar, S. M. Susceptibility to Mycobacterium tuberculosis:
lessons from inbred strains of mice. Tuberculosis 83, 279–285 (2003).
37. Chackerian, A. A., Alt, J. M., Perera, T. V., Dascher, C. C. & Behar, S. M. Dis-
semination of Mycobacterium tuberculosis is inﬂuenced by host factors and pre-
cedes the initiation of T-cell immunity. Infect. Immun. 70, 4501–4509 (2002).
38. Grifﬁths, K. L. et al. Targeting dendritic cells to accelerate T-cell activation over-
comes a bottleneck in tuberculosis vaccine efﬁcacy. Nat. Commun. 7, 13894
(2016).
39. von Both, U. et al. Mycobacterium tuberculosis exploits a molecular off switch of
the immune system for intracellular survival. Sci. Rep. 8, 661 (2018).
40. Baena, A. & Porcelli, S. A. Evasion and subversion of antigen presentation by
Mycobacterium tuberculosis. Tissue Antigens 74, 189–204 (2009).
41. Bru, A. & Cardona, P. J. Mathematical modeling of tuberculosis bacillary counts
and cellular populations in the organs of infected mice. PLoS ONE 5, e12985
(2010).
42. Florido, M. et al. Pulmonary immunization with a recombinant inﬂuenza A virus
vaccine induces lung-resident CD4(+) memory T cells that are associated with
protection against tuberculosis. Mucosal Immunol. 11, 1743–1752 (2018).
43. Manjaly Thomas, Z. R. & McShane, H. Aerosol immunisation for TB: matching
route of vaccination to route of infection. Trans. R. Soc. Trop. Med. Hyg. 109,
175–181 (2015).
44. Wang, J. et al. Single mucosal, but not parenteral, immunization with recombi-
nant adenoviral-based vaccine provides potent protection from pulmonary
tuberculosis. J. Immunol. 173, 6357–6365 (2004).
45. Afkhami, S., Yao, Y. & Xing, Z. Methods and clinical development of adenovirus-
vectored vaccines against mucosal pathogens. Mol. Ther. Methods Clin. Dev. 3,
16030 (2016).
46. Van Dis, E. et al. STING-activating adjuvants elicit a Th17 immune response and
protect against Mycobacterium tuberculosis infection. Cell Rep. 23, 1435–1447
(2018).
47. Orr, M. T. et al. Mucosal delivery switches the response to an adjuvanted
tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses with-
out impacting the protective efﬁcacy. Vaccine 33, 6570–6578 (2015).
48. Aguilo, N. et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers
protection to tuberculosis-susceptible mice by an interleukin 17-dependent
mechanism. J. Infect. Dis. 213, 831–839 (2016).
49. Pitt, J. M. et al. Blockade of IL-10 signaling during bacillus Calmette–Guerin
vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma
and IL-17 responses and increases protection to Mycobacterium tuberculosis
infection. J. Immunol. 189, 4079–4087 (2012).
50. Woodworth, J. S. et al. Protective CD4 T cells targeting cryptic epitopes of
Mycobacterium tuberculosis resist infection-driven terminal differentiation. J.
Immunol. 192, 3247–3258 (2014).
51. Monin, L. et al. Immune requirements for protective Th17 recall responses to
Mycobacterium tuberculosis challenge. Mucosal Immunol. 8, 1099–1109 (2015).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T. . .
JS Woodworth et al.
826
Mucosal Immunology (2019) 12:816 – 826
